Obexelimab in Systemic Lupus Erythematosus With Exploration of Response Based on Gene Pathway <scp>Co‐Expression</scp> Patterns: A <scp>Double‐Blind</scp>, Randomized, <scp>Placebo‐Controlled</scp>, Phase 2 Trial

Abstract

Although the primary endpoint was not reached, secondary analysis showed time to LOI was significantly increased in obexelimab-treated patients, and analysis of patient subsets defined by gene expression patterns at baseline suggests a responding subpopulation.